Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT02997228
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
- NCT02997228 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on NCT02997228 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02997228 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7
- Interventions
- Atezolizumab; Bevacizumab; Biospecimen Collection; Computed Tomography; Fluorouracil; Leucovorin; Magnetic Resonance Imaging; Oxaliplatin; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (bevacizumab, mFOLFOX6) · Active comparator
- Arm II (atezolizumab) · Experimental
- Arm III (atezolizumab, bevacizumab, mFOLFOX6) · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Progression free survival (PFS)
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jan 19, 2018
- Primary completion
- Jun 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02997228 · updated Oct 26, 2026
Publications
linked from the registry- Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026 Oct 10;44(29):2824-2834. doi: 10.1200/JCO-25-03052. Epub 2026 Jul 29. PubMed 42525921